Ionization x-ray electron-beam detector

FIELD: medical equipment; X-ray diagnostics.

SUBSTANCE: device can be used in X-ray digital visualization systems. X-ray electron-beam detector has case, conversing member, collecting electrode, deflection system and electron searchlight. Conversing member has to be air-proof gas ionization chamber, which has drift electrode to be output window of the case. Electrodes of signal electrode system of air-proof ionization chamber are withdrawn onto surface of the chamber at the side of collecting electrode, deflection system and electron searchlight.

EFFECT: improved counting characteristics; higher quality of image; widened field of X-ray check.

1 dwg

 

The proposed x-ray ionization electron beam detector is designed for use in digital x-ray imaging systems, in particular, in x-ray devices for medical diagnosis.

Similar detectors used in x-ray installations for reception of the density distribution of the radiation flux at the output of the object (see Rechentechnik: a Handbook. 2 kN. Book 1./ Under the General Ed. VLA. - M.: Mashinostroenie, 1992. - S-160; patent 96108319 EN, IPC 6 H 01 J 31/58 published 10.27.98 year). These detectors contain a housing with an input window, a deflecting system that converts an element (a photoconductive target or microchannel plate), located parallel to the plane of the entrance window, electronic spotlight, located in a vacuum environment by transforming element, not converted to the input window. The x-ray beam through the input window gets to the converting element and interacts with it. The resulting interaction potential relief is read by scanning an electron beam generated by electronic spotlight.

These detectors inherent narrow field x-ray control, which is a field conversion element, a considerable inertia and low efficiency registration rentgenovsk the th radiation, due to the properties of the transforming element.

The closest in technical essence is the detector described in patent 96108319 EN, IPC 6 H 01 J 31/58 published 10.27.98, This detector includes a housing, a deflector system, converting element located parallel to the plane of the entrance window of the detector, the collector electrode and electronic spotlight, located in a vacuum environment by transforming element, not converted to the input window. Transforming element is a microchannel plate, which performs simultaneously the function of the reinforcement element. The x-ray beam through the input window gets to the converting element and interacts with it. The resulting interaction on the surface of the conversion element to the e-spotlight potential relief is read by scanning an electron beam generated by electronic spotlight.

Use as a transformative element of a microchannel plate complicates the design and manufacturing technology of the detector. The considerable inertia of microchannel plates is not possible to increase the rate of events, and technological limitations on the increase in the size and thickness of the microchannel plate does not allow to increase the x-ray field to the of ntrolle and the detection efficiency of x-ray radiation.

The technical result of the present invention is to increase the count rate of events, field x-ray control and the detection efficiency of x-ray radiation. In addition, simplifies the design of the detector and reduced technological difficulties in its manufacture.

Task to be solved by the claimed invention is directed, is achieved by the fact that in the known x-ray detector, comprising a housing, a transformative element, the collector electrode, deflecting system and electronic light transformative element is a sealed gas ionization chamber, the drift electrode which is also the input window of the housing and the electrode system of the signal electrodes sealed gas ionization chamber displayed on its surface side located in the vacuum manifold ring-shaped electrode, deflecting system and electronic spotlight.

The drawing shows schematically a General view of the x-ray ionization electron beam detector.

Ionization x-ray electron beam detector contains an annular collector electrode 1, e floodlight 2, the deflecting system 3, building 4, transformative element representing a sealed gas ionization chamber 5 containing the drift the electrode 6, which is also the input box body 4, and a system of signal electrodes 7, the electrodes of which are end-to-end isolated from other conductors, discretely distributed over the surface and volume of a gas-tight dielectric plate, and displayed on the surface of the sealed gas ionization chamber from the side of the collector ring-shaped electrode 1 and e-floodlight 2. The internal volume of the transformative element of the detector is filled with a gas, and the rest of the volume of the detector is supported by a high vacuum. To the drift electrode 6 is applied a positive potential relative to the cathode of an electron spotlight 2, and to the collector ring-shaped electrode 1 and a negative potential relative to the cathode of an electron spotlight 2.

The device operates as follows. Gamma-quanta of radiation flux passing through the input window of the housing 4, which is also the drift electrode 6 sealed gas ionization chamber 5 communicate with filling it with gas. Formed by the interaction of the electrons under the influence of an electric field generated by the drift electrode 6, move to this electrode, and the ions to the signal electrodes 7. When the deposition of ions on the electrode system of the signal electrodes 7 are partially offset by negative p the surface evenly distributed charge, available on these electrodes after the preliminary cycle of the scanning electron beam, and is formed of the charge relief corresponding to the intensity distribution of the radiation flux from the object of observation. When the next scanning electrode system of the signal electrodes 7 electron beam latter will restore the original capacity of these electrodes, resulting in a signal taken from the collector ring-shaped electrode 1 will contain information about the original x-ray image.

At least x-ray ionization electron beam detector may be a one-coordinate.

Using transformative element representing a sealed gas ionization chamber, instead of converting element representing a microchannel plate, distinguishes the proposed detector from the specified prototype, as it leads to improvement of the counting characteristics of the detector, increasing the field of x-ray control, increasing the detection efficiency γ-quanta that can reduce the dose received by the object control. In addition, simplified and reduced the price design and production technology of the detector.

X-ray electron beam detector including a housing, a transformative element, Kollek, who priori electrode, the deflecting system and electronic spotlight, characterized in that the transforming element is a sealed gas ionization chamber, the drift electrode which is also the input window of the housing and the electrode system of the signal electrodes sealed gas ionization chamber displayed on its surface facing the collector electrode, deflecting system and electronic spotlight.



 

Same patents:

FIELD: measuring engineering.

SUBSTANCE: device comprises recording unit, housing of the aspiration ionization chamber provided with the inlet insulated device for sucking the ionized composition of gas, measuring device mounted in the housing, and fan. The housing receives a deflecting capacitor. The back wall of the aspiration ionization chamber is made of an insulating material and is undulant and perforated. The measuring device is made of measuring capacitors whose first plates are rectangular perforated electrodes mounted in the hollows of the undulant back wall. The second plates of the capacitors are set in the crests of the undulant back wall. The measuring capacitors and recording device are divided into three sections. The left section is used for recording negatively charged ions, the central section is used for recording total ionization, and the right section is used for recording positively charged ions.

EFFECT: expanded functional capabilities.

2 dwg

The invention relates to the field of nuclear physics and can be used to control the operation of nuclear reactors

FIELD: medicine, pediatrics, hematology.

SUBSTANCE: the present innovation could be applied in treating surgical and oncological diseases in children during treating and preventing anemia of different etiology. One should introduce ceruloplasmin at daily single dosage ranged 50-200 mg depending upon child's age against 100-200 ml 0.9%-sodiumchloride solution intravenously by drops at the rate of 40-50 drops/min. Moreover, for preventing and/or treating posthemorrhagic anemia in case of surgical operations one should introduce ceruloplasmin during 2 d before surgical operation, intraoperationally, and for 2-10 d after operation. For preventing and/or treating anemia in case of purulent-septic diseases ceruloplasmin should be introduced during chemotherapeutic days during the whole period of the course conducted, for preventing and treating radiation anemia at the background of radiation therapy ceruloplasmin should be injected once weekly during the whole period of radiotherapy course, for preventing and treating toxic and radiation anemia at the background of chemoradiation therapy ceruloplasmin should be introduced once weekly on the day of chemotherapy during the whole course of chemoradiation treatment. The innovation enables to avoid inflows of erythrocytic mass and donor's blood along with shortened number of procedures on introduction of ceruloplasmin and 4-times decrease in the risk for the development of severe anemia in children due to matching peculiar mode for ceruloplasmin introduction.

EFFECT: higher efficiency of therapy and prophylaxis.

4 cl, 5 ex

FIELD: medicine, oncology.

SUBSTANCE: one should carry out chemoradiation therapy at applying a cytostatic preparation followed by distance and intracavitary irradiation. Depending upon development of tumor lesion during the first 3 or 6 d it is necessary to conduct monochemotherapy only due to introducing proxiphen together with dimethyl sulfoxide at weight ratio of 4.5-5.0 : 0.5-1.5, correspondingly by applications in "Coletex" napkins. Moreover, a napkin should be pre-impregnated in 20%-dimethylsulfoxide solution and fixed with a tough vaginal tamponade by changing napkins every 24 h. Then since the 4th d or the 7th d simultaneously with application it is necessary to carry out contact irradiation and distance impact onto minor pelvis every 4-6 h at single focal dosage (SFD) being 2 Gy at 10 seances 5 times/weekly with high-activity sources of SFD 2 Gy. The innovation provides tumor regress under conditions of no therapeutic complications, thus, improving patients' quality of life.

EFFECT: higher therapy.

3 ex

FIELD: oncology.

SUBSTANCE: invention is directed, in particular, to treatment of patients with Ewing's sarcoma and osteogenic sarcoma at different stages of malignant process. Method comprises chemotherapy and beam therapy. Samples of venous blood are taken from children in age of 5 to 12 years in amounts not larger than 5% of the total volume of circulating blood per 1 introduced dose of chemical preparation and, from adolescents and young persons, in amount of 200 ml. Then 4 courses of polychemotherapy are fulfilled with autoblood according to standard treatment schemes for given diseases, taking into account stages of disease, in recommended doses. Between 2nd and 3rd chemotherapy courses, radiotherapy is fulfilled on metastatic focuses in lungs. After 4 courses of induction autohemo-chemotherapy, local therapy on the primary focus (radiotherapy and/or surgical treatment) is fulfilled and also radiotherapy on metastatic focuses in other bones, after which follows consolidation involving chemical preparation of the second line.

EFFECT: improved remote results of treatment , suppressed metastatic focuses, reduced tumor dimensions, and weakened toxic manifestations of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with measuring radioactivity in alive organisms and could be applied for detecting really absorbed dosage under conditions of intra-operational impact. The method suggested includes detecting clinical volume for the target of radiation impact including the volume of healthy tissues to be subjected for radiation impact, developing the plan of radiation impact based upon data obtained with the help of tissue-equivalent phantoms, location in interest sites of clinical volume of sterilized separate fragments of dosimetric device being the matrix of functional units and designed as thermoluminescent detectors being hermetically isolated at the distance of 10 mm between their edges and fixed between the layers of flexible biocompatible material, registering the location of detectors, performing the séance for intra-operational radiation therapy followed by removing the fragments of dosimetric device out of target's volume. Information should be read from thermoluminescent detectors.

EFFECT: higher accuracy of measuring.

1 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating malignant tumors of central bronchi and trachea due to argonoplasmatic recanalization of tracheal lumen and/or bronchi, at power being 60-90 W followed by brachitherapy at source's trajectory length being 5-20 cm, pace of 5 mm and the depth of reference isodose being 10 mm against the source. Moreover, one should move applicator above and below the tumor ranged 1-3 cm to apply the dose ranged 14-28 Gy once weekly per 7 Gy. Additionally, one should carry out distance radiation therapy 5 times weekly per 1-2 Gy up to total focal dose of 30-40 Gy. The present innovation enables to highly increase the passability of respiratory tract in case of malignant stenosis and prevent the development of their relapse.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, neurooncology.

SUBSTANCE: one should carry out chemotherapy and irradiation till radical dosage. Moreover, 2-3 d before the onset of radiation therapy and during the whole course of irradiation one should indicate the intake of indometacin at daily dosage being 300 mg, and 8-14 d before the end of therapy course or the stage of radiation therapy it is necessary to conduct chemotherapeutic cycle with vincristine at total dosage being 4 mG and lomustine at total dosage 160-240 mg. At performing a split course of irradiation the intake of indometacin should be indicated between the stages. The innovation enables to increase radio sensitivity of malignant tumor, suppress angiogenesis, proliferative activity and increased cytotoxic activity of chemopreparations.

EFFECT: higher efficiency of therapy.

1 cl, 3 ex

FIELD: medicine, oncology, gynecology.

SUBSTANCE: method involves external irradiation and using chemopreparations combined with autoplasma. External irradiation in the dose 2 Gr is carried out from 1 to 4 day of treatment followed by intravenous administration of cisplatin on 5 day in the dose 10 mg with 250 ml of physiological solution. On the following day 10 ml of autoplasma incubated with 10 mg of cisplatin is administrated by paratumoral route by right and left of tumor into paravaginal cellular tissue and by intratumoral route into projection of cervical channel. Blood cellular elements are incubated with 600 mg of cyclophosphane and reinfused by intravenous drop route. Effects are repeated in indicated sequence once per a week, 4 times per treatment course. Method provides increasing percent of tumor regression due to the complex effect on tumor, enhancing the topical concentration of cytostatic drug and prolongation of its contact in malignant growth zone, and providing radiosensibilizing effect in diminishing the general toxic effect of therapy. Invention can be used in treatment of patients with topically disseminated forms of uterus cervix cancer at the stage T3NxM0.

EFFECT: improved and enhanced treatment method.

1 ex

FIELD: medicine, oncourology.

SUBSTANCE: the present innovation deals with conservative treatment of patients with malignant prostatic tumor at different stages. The method includes testicular enucleation, introduction of anti-tumor chemopreparations and radiation therapy. Moreover, in the onset of radiation therapy one should introduce 25 mg Cisplatin incubated with 10 ml patient's plasma into both prostatic lobes and paraprostatic fiber from the right and from the left. At achieving a focal dosage of 20 Gy one should repeat introduction of chemopreparation in similar dosage, and radiation therapy should be continued up to total focal dosage of 40 Gy. The innovation enables to decrease tumor sizes, side manifestations of radiation therapy at decreasing radiation loading and improve patient's life quality due to mitigating the urination.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, oncology.

SUBSTANCE: before irradiation it is necessary to cool the tumor to achieve the temperature of freezing at clinically detectable border between the tumor and healthy tissue to perform irradiation directly after natural tissue defrosting with a single focal dosage (SFD) being 2-2.5 Gy daily for 5 d a week at 2-d-long interval to achieve total focal dosage (TFD) of 60-65 Gy. Moreover, the area of healthy tissue should be protected with a shielding applicator - a lead plate - during irradiation. The present innovation enables to maximally keep anatomical relief and function of local tissues.

EFFECT: higher efficiency of therapy.

1 cl, 4 ex

FIELD: medicine, oncology.

SUBSTANCE: the method deals with applying chemopreparations incubated with autolymph and radiation therapy. Lymph taken out of patient's thoracic duct should be centrifuged for 30 min at 2200 rot./min, lymphatic plasma should be taken and frozen at -40 C, lymphatic formic elements should be incubated in a thermostat at 37 C for 1 h together with chemopreparations by a certain scheme to be reinfused for a patient intravenously by drops according to the given scheme. Then, 2 wk later, one should perform therapy with a split course of distance gammatherapy at single focal dosage (SFD) of 4 Gy. At the first stage one should apply per 2 Gy twice daily at 4-5-h-long interval 5 times weekly, at achieving focal dosage of 28 Gy it is necessary to have a week-long interval. Then radiation therapy should be continued but SFD of 4 Gy should be applied at once. One should fulfill 3 fractions of irradiation per a week, there are 6 fractions during the second stage, totally. Total focal dosage (TFD) per the whole course of irradiation corresponds to 52 Gy. About 4 wk after radiation therapy one should defrost lymphatic plasma to incubate it with the same chemopreparations in a thermostat at 37 C for 1 h to be then reinfused for a patient intravenously by drops. The method enables to decrease tumor volume and tumor process metastasing without any operative interference.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, oncology.

SUBSTANCE: invention relates to a method for treatment of uterus body topically spread cancer involving applying chemotherapy and intrauterus irradiation. Method is carried out by the following manner: at the 1-st day of treatment cyclophosphan is administrated in the dose 1200-1600 mg by interstitial paratumoral route; at the 2-d day cream-like based fluorouracil in the dose 300-550 mg or adriablastin in the dose 20-30 mg is administrated into uterus cavity; on the next day sйance of intracavitary irradiation is carried out in the dose 10 Gr. All these procedures are repeated three times with interval for 6 days. Method provides high topical concentrations of chemopreparations in tumor zone in reducing their adverse toxic effect that results to the curative effect of patients of elderly age with accompanying therapeutic diseases.

EFFECT: improved method for treatment.

1 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out argon plasma of tracheal and/or bronchial lumen recanalization by applying power of 60-90 W with argond discharge rate being 2.0-2.4 l/min large. Brachitherapy is applied next to it moving the source with 5 mm large step. Trajectory length is 5 to 20 cm large. Reference isodose depth is 10 mm far from the source with applicator moving above and below the tumor from 1 to 3 cm. Dose from 14 to 28 Gr is to be administered once a week in 7 Gr large portions.

EFFECT: enhanced effectiveness of treatment; reduced risk of complications; prolonged remission period.

FIELD: medical equipment; radiation therapy.

SUBSTANCE: radioactive source has radioisotope disposed inside air-tight biocompatible container. At least some part of container is made profiled and have rough, non-smooth surface. Radioactive source is made by loading it inside air-tight container. Composition has assemblage of radioactive sources mounted in line onto biologically decomposed material. Invention helps to improve ultrasonic visibility of source and/or reduce the trend of source to migrate in patient's body after implantation.

EFFECT: improved quality of treatment.

22 cl, 8 dwg

FIELD: medicine.

SUBSTANCE: the innovation deals with irradiating lymphatic collector, that is: at the first stage it is necessary to perform irradiation for the whole volume of affected lymph collector at total focal dose being 26 Gy, at the second stage one should carry out irradiation at collector's areas depending upon the degree of their destruction at decreasing the size of fields: for the area of residual lymph nodes remained after polychemotherapy - up to the total focal dose being 44 Gy, for the area of massively affected lymph nodes in case of total effect after polychemotherapy - up to 36 Gy, for the area of moderately affected lymph nodes in case of total effect after polychemotherapy - up to 30 Gy. The method enables to decrease the number of complications and local relapses, shorten terms for therapy, improve values for patients' survival rate at decreasing total integral dose of irradiation.

EFFECT: higher efficiency of radiation therapy.

2 ex

Up!